Last reviewed · How we verify
Topical suspension vehicle
A topical suspension vehicle is a pharmaceutical formulation designed to deliver active ingredients to the skin surface through a liquid suspension base.
A topical suspension vehicle is a pharmaceutical formulation designed to deliver active ingredients to the skin surface through a liquid suspension base. Used for Vehicle/excipient for topical dermatological formulations.
At a glance
| Generic name | Topical suspension vehicle |
|---|---|
| Also known as | Vehicle, TolaSure Vehicle Gel, Placebo |
| Sponsor | LEO Pharma |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Topical suspension vehicles are inert or minimally active formulation bases used to suspend solid particles or active pharmaceutical ingredients for application to the skin or mucous membranes. They facilitate uniform distribution, absorption, and retention of therapeutic agents at the site of application while providing appropriate viscosity, stability, and skin compatibility.
Approved indications
- Vehicle/excipient for topical dermatological formulations
Common side effects
Key clinical trials
- A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1) (PHASE2, PHASE3)
- A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2) (PHASE3)
- LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs) (PHASE3)
- B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis (PHASE2)
- Study Evaluating the Efficacy and Safety of OCS-01 Eye Drops in Subjects Following Cataract Surgery (PHASE3)
- Topical Application of Imiquimod Gel at Different Concentrations in Actinic Cheilitis (PHASE1)
- Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Atopic Dermatitis (PHASE2)
- A Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Rosacea (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Topical suspension vehicle CI brief — competitive landscape report
- Topical suspension vehicle updates RSS · CI watch RSS
- LEO Pharma portfolio CI